Notable FDA decisions expected for fourth quarter 2024 include: New indication for tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea and obesity Accelerated Approvals for two Orphan Drugs a one-time gene therapy for an ultrarare protein deficiency and a drug for biliary tract cancer CAR T cell therapy for bone marrow cancer Several agents for rare diseases o First-in-class encapsulated cell therapy implant for a neurodegenerative ophthalmic disorder o Oral option for classic congenital adrenal hyperplasia, related to an enzyme deficiency o Injectable for familial chylomicronemia syndrome, characterized by severe hypertriglyceridemia o Injectable for short bowel syndrome with intestinal failure Maryam Tabatabai Vice President, Clinical Information Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Clinical Pharmacist, Drug Information Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Director, Pipeline Consultant panel Robert Greer, RPh, BCOP Vice President, Clinical Strategy and Programs Andrea Henry, PharmD, MBA, BCPS Specialty Drug Information Pharmacist Katie Lockhart Director, Trend and Forecasting Analytics Olivia Pane, PharmD, CDCES Clinical Pharmacist, Drug Information Devon Trumbower, PharmD, BCPS Clinical Pharmacist All brand names are property of their respective owners
[26] [27] When starting GLP-1 treatment, many patients experience a significant reduction in appetite and early satietyfeeling full after consuming smaller portions
GLP-1 receptor The GLP-1 receptor, often referred to as GLP-1R, is a G protein-coupled receptor (GPCR) that binds to GLP-1
Most people notice initial effects within the first few weeks, with more significant results appearing over several months
Durden, E., Liang, M., Fowler, R., Panton, U
